Antepartum vitamin K and phenobarbital for preventing intraventricular hemorrhage in the premature newborn: A randomized, double-blind, placebo-controlled trial

J. A. Thorp, J. Parriott, D. Ferrette-Smith, B. A. Meyer, G. R. Cohen, J. Johnson

Research output: Contribution to journalArticle

22 Scopus citations


Objective: To determine whether antepartum phenobarbital and vitamin K reduce the risk of intraventricular hemorrhage in premature newborns. Methods: Patients at imminent risk for spontaneous or indicated premature delivery between 24-34 weeks' gestation were randomized to receive either placebo or vitamin K and phenobarbital. All patients received betamethasone and antibiotics and were managed uniformly by a single perinatal group in one hospital. All newborns were managed uniformly in the same facility by a single neonatal group. Results: There was a nonsignificant reduction in all grades of intraventricular hemorrhage in the treatment group when compared to the placebo group (48.2 versus 38.3%; P > .05). Frequencies were reduced for severe intraventricular hemorrhage (grades 3 and 4) (6.0 versus 2.5%; P > .05) and mild intraventricular hemorrhage (grades 1 and 2) (42.2 versus 35.8%; P > .05). Conclusions: Antepartum phenobarbital and vitamin K effected a nonsignificant reduction in both mild and severe intraventricular hemorrhage. The incidence of severe intraventricular hemorrhage in our control group was significantly less than that observed in previous studies.

Original languageEnglish (US)
Pages (from-to)70-76
Number of pages7
JournalObstetrics and Gynecology
Issue number1
Publication statusPublished - 1994


ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this